Exchange Traded Concepts LLC decreased its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report) by 16.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 45,260 shares of the company’s stock after selling 8,935 shares during the quarter. Exchange Traded Concepts LLC owned 0.06% of Sutro Biopharma worth $157,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. ProShare Advisors LLC increased its position in shares of Sutro Biopharma by 49.1% during the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after purchasing an additional 5,373 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Sutro Biopharma during the 1st quarter valued at about $92,000. The Manufacturers Life Insurance Company increased its position in shares of Sutro Biopharma by 27.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock valued at $97,000 after purchasing an additional 7,082 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Sutro Biopharma by 24.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock valued at $102,000 after purchasing an additional 3,578 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Sutro Biopharma by 134.6% during the 3rd quarter. SG Americas Securities LLC now owns 34,662 shares of the company’s stock valued at $120,000 after purchasing an additional 19,890 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.
Sutro Biopharma Price Performance
STRO stock opened at $3.64 on Tuesday. Sutro Biopharma, Inc. has a 1-year low of $2.01 and a 1-year high of $6.13. The company has a market capitalization of $298.33 million, a price-to-earnings ratio of -1.99 and a beta of 1.17. The business has a 50 day simple moving average of $4.01 and a two-hundred day simple moving average of $3.86.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on STRO shares. Truist Financial reduced their price target on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 16th. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Sutro Biopharma in a research note on Friday, October 11th. Piper Sandler reiterated an “overweight” rating and set a $11.00 price objective on shares of Sutro Biopharma in a research note on Friday, October 11th. Finally, JMP Securities reiterated a “market outperform” rating and set a $17.00 price objective on shares of Sutro Biopharma in a research note on Monday, September 16th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $12.13.
Get Our Latest Research Report on Sutro Biopharma
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Further Reading
- Five stocks we like better than Sutro Biopharma
- Manufacturing Stocks Investing
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- What is the Dogs of the Dow Strategy? Overview and Examples
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding STRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report).
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.